» Articles » PMID: 6950170

Growth and Characterization of Childhood Rhabdomyosarcomas As Xenografts

Overview
Specialty Oncology
Date 1982 Mar 1
PMID 6950170
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Eleven surgical specimens of childhood rhabdomyosarcoma (RMS), two bone marrow samples, and cells from ascitic fluid from 1 patient were implanted sc into immune-deprived inbred CBA/CaJ mice. From these, seven lines of RMS were obtained as xenografts, each retaining the histologic characteristics of the tumor of origin and human lactate dehydrogenase isozymes; these represented 6 of the 11 surgical specimens, whereas one line originated from the transplanted cells from ascitic fluid. It was concluded that children RMS has a fairly high frequency of heterotransplantability in this system and that such a laboratory model may prove useful in the development of new therapeutic regimens in this disease.

Citing Articles

Comprehensive characterization of patient-derived xenograft models of pediatric leukemia.

Rogojina A, Klesse L, Butler E, Kim J, Zhang H, Xiao X iScience. 2023; 26(11):108171.

PMID: 37915590 PMC: 10616347. DOI: 10.1016/j.isci.2023.108171.


EphA1 receptor tyrosine kinase is localized to the nucleus in rhabdomyosarcoma from multiple species.

LaCombe R, Cecchini A, Seibert M, Cornelison D Biol Open. 2022; 11(10).

PMID: 36214254 PMC: 9581518. DOI: 10.1242/bio.059352.


Developing New Agents for Treatment of Childhood Cancer: Challenges and Opportunities for Preclinical Testing.

Ghilu S, Kurmasheva R, Houghton P J Clin Med. 2021; 10(7).

PMID: 33916592 PMC: 8038510. DOI: 10.3390/jcm10071504.


PCAT: an integrated portal for genomic and preclinical testing data of pediatric cancer patient-derived xenograft models.

Yang J, Li Q, Noureen N, Fang Y, Kurmasheva R, Houghton P Nucleic Acids Res. 2020; 49(D1):D1321-D1327.

PMID: 32810235 PMC: 7778893. DOI: 10.1093/nar/gkaa698.


Challenges and Opportunities for Childhood Cancer Drug Development.

Houghton P, Kurmasheva R Pharmacol Rev. 2019; 71(4):671-697.

PMID: 31558580 PMC: 6768308. DOI: 10.1124/pr.118.016972.